Bank Of New York Mellon Corp I Teos Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$13.02 - $22.62 $3.41 Million - $5.93 Million	261,955 New	261,955 $3.57 Billion
Q4 2022 Feb 14, 2023	BUY	$17.77 - $21.6 $4.88 Million - $5.93 Million	274,373 New	274,373 $5.36 Million
Q3 2022 Nov 14, 2022	BUY	$18.6 - $27.25 $628,308 - $920,505	33,780 Added 18.71%	214,291 $4.08 Million
Q2 2022 Aug 15, 2022	SELL	$16.57 - $35.1 $104,208 - $220,743	-6,289 Reduced 3.37%	180,511 $3.72 Million
Q1 2022 May 11, 2022	BUY	$31.92 - $47.45 $2.69 Million - $3.99 Million	84,186 Added 82.04%	186,800 $6.01 Million
Q4 2021 Feb 11, 2022	BUY	$26.23 - $47.86 $817,169 - $1.49 Million	31,154 Added 43.6%	102,614 $4.78 Million
Q3 2021 Nov 12, 2021	BUY	$23.91 - $29.58 $318,720 - $394,301	13,330 Added 22.93%	71,460 $1.93 Million
Q2 2021 Aug 11, 2021	BUY	$17.9 - $36.1 $54,040 - $108,985	3,019 Added 5.48%	58,130 $0
Q1 2021 May 13, 2021	BUY	$30.86 - $44.2 $427,441 - $612,214	13,851 Added 33.57%	55,111 $0
Q4 2020 Feb 09, 2021	BUY	$21.59 - $33.95 $263,203 - $413,884	12,191 Added 41.94%	41,260 $0
Q3 2020 Nov 12, 2020	BUY	$17.57 - $32.92 $510,742 - $956,951	29,069 New	29,069 $0

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.